Hey readers! Here's an uncomfortable thought to open with: a therapy can look great on paper while quietly hiding its most dangerous side effect. That's the argument at the heart of this issue's lead story, and it has real stakes for anyone with type 1 diabetes weighing a GLP-1 add-on. We've also got a landmark CV approval, a first-of-its-kind wearable, and a cluster of cell-therapy results worth watching.
🩸 The reporting gap in GLP-1 add-on trials
GLP-1RA Type 1 Diabetes Trials Criticized for Inadequate Hypoglycemia Reporting argues that GLP-1 receptor agonist add-on studies in type 1 diabetes have documented the benefits carefully while leaving the risk side underexamined. A systematic review and meta-analysis of 21 randomized controlled trials (3,417 participants) found significant cardiometabolic improvements, including a weighted mean HbA1c reduction of -0.21 percentage points, but the critique says hypoglycemia has not been evaluated with the same rigor.
But a letter published in Endocrinology, Diabetes & Metabolism argues that the evidence base remains incomplete unless it reports hypoglycemia - the potentially life-threatening fall in blood glucose - with the same precision as the benefits.
Why this matters for T1D specifically: everyone here is insulin-dependent, so a drug that shifts glucose downward carries a different risk profile than it does in type 2. The authors point to the ADJUNCT ONE and ADJUNCT TWO liraglutide trials, where liraglutide was associated with higher symptomatic hypoglycemia event rates than placebo at both the 1.8 mg and 1.2 mg doses, plus ketosis concerns in ADJUNCT ONE. They also flag additional safety-related patterns from the FDA's FAERS database.
The fix they propose is refreshingly concrete. Future reviews should predefine hypoglycemia as a primary safety outcome, sort events by severity and by nocturnal versus daytime timing, separate results by agent and dose, and use standardized classification such as the International Hypoglycemia Study Group's levels (Level 1 defined as glucose at or below 3.9 mmol/L, or 70 mg/dL).
The authors propose that future systematic reviews should define hypoglycemia in advance as a primary safety outcome and divide it into clinically informative categories.
The takeaway isn't "avoid GLP-1s." It's that a benefit-to-risk conversation with your endocrinologist needs both halves of the ledger, and right now the published evidence gives you one half in higher resolution than the other. - Endocrinology, Diabetes & Metabolism, via Scienmag
💊 The GLP-1 headline that shifts the backdrop
The same week that critique landed, the GLP-1 class got a major win in type 2 diabetes, which is worth understanding because it colors how these drugs get studied and prescribed.
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes reports that on Aug. 28, 2026, the FDA cleared Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, on top of its existing blood-sugar indication. The decision rests on SURPASS-CVOT, described as the first head-to-head cardiovascular outcomes trial between two incretin medicines, enrolling 13,299 participants across 30 countries over roughly five years.
"In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3)."
A point worth reading carefully: Mounjaro hit non-inferiority (hazard ratio 0.92; 95.3% CI: 0.83, 1.01), and superiority to dulaglutide was not established. So the honest framing is "as good as, with an 8% lower rate," not "clearly better." Pharmaceutical Technology's coverage adds that this is the first GIP/GLP-1 therapy approved in the US for CV risk reduction, following Wegovy's approval for the same purpose in March 2024. The most common adverse events were gastrointestinal and mostly mild-to-moderate during dose escalation. This is a type 2 indication, not type 1, but it explains the intense interest in getting incretin-based add-ons right for T1D too. - PR Newswire and Pharmaceutical Technology
🔬 Ketones you can watch in real time
FDA authorizes first wearable to track both ketones and blood sugar covers the authorization of Abbott's Libre Duo 10 Day, described as the first wearable to continuously track ketones and the first device anywhere to monitor ketones and glucose at once. It reads both from the fluid beneath the skin every minute and can alert your phone when ketones climb.
The rationale connects directly to the ketosis worries that show up in GLP-1 and SGLT2 discussions. DKA can escalate within hours, and the FDA noted that hospital admissions for DKA have risen 55% over the past decade. Point-in-time blood or urine tests can't show whether ketones are rising or falling.
"Knowing that ketone levels are rising, and having that information in real time, around the clock, can be the difference between early intervention and a life-threatening emergency," said Dr. Michelle Tarver, who directs the FDA's Center for Devices and Radiological Health.
Per this article, the authorization is supported by six studies covering more than 600 people. Abbott's own announcement adds that the device earned De Novo authorization after a breakthrough device designation, meets the iCGM and iCGK standards, and is expected to launch in the US later in 2026 with planned compatibility across several AID pump makers. Breakthrough T1D points out that most people with T1D lack home tools to measure ketones at all, which is a big part of why continuous tracking could change how early DKA gets caught. - Medical Xpress, BioSpace, Breakthrough T1D
🧬 Cell and gene therapy: promising, and still honest about limits
A cluster of cell-therapy results dropped this month. The common thread is immune tolerance without lifelong immunosuppression, and the results range from striking to sobering.
Stanford's new cell therapy cures type 1 diabetes in mice reports that combining hematopoietic stem cells and islet cells from mismatched donors created a "hybrid immune system," with 19 of 19 mice protected from developing T1D and 9 of 9 mice with established disease fully cured, and no graft-versus-host disease. The authors note key steps already exist in clinical stem-cell transplant practice. - Journal of Clinical Investigation, via Cancerilles
This new treatment might cure type 1 diabetes describes Uppsala researchers who used CRISPR-Cas12b to edit donor insulin-producing cells so they survived and functioned for 14 months without rejection and without immunosuppressants. Scaling to enough cells is the next challenge. - Welltica
New "Invisible" Cell Therapy Could Provide Side-Effect-Free Diabetes Treatment reports a Penn State hydrogel coating (BZP) that kept diabetic mice diabetes-free for more than 100 days without continuous immunosuppression. - SciTechDaily
Gene-Edited Beta Cells for Insulin Treatment in Type 1 Diabetes is the useful counterweight: disabling RNLS or HIVEP2 alone did not protect transplanted beta cells in immunocompetent mice, suggesting durable protection needs combined strategies. - Koc University, via MedBound Times
"We need to not only replace the islets that have been lost but also reset the recipient's immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
Read these together and the picture is encouraging but early: mouse data and small human safety work, not approved cures. The MedBound study is a helpful reminder that single-target fixes often fall short.
📋 Also worth your attention
Type 1 diabetes drug unable to secure PBS listing reports that Australia's PBAC recommended against listing Tzield (teplizumab) for stage 2 T1D, citing uncertain long-term benefit and value at the requested price; Sanofi says it will resubmit. - RACGP
Teplizumab: A Drug to Delay Type 1 Diabetes notes teplizumab is available on the NHS in England and Wales, with a published course price around GBP 150,000 and a confidential discount, and that access hinges on early detection before symptoms appear.
New Study: Intermittent Fasting Lowers Blood Sugar in Type 1 Diabetes reports a UIC randomized trial where time-restricted eating (an eight-hour window) lowered HbA1c by about 0.5% over six months without raising DKA or severe glucose swings. Published in Diabetes Care on 17 August 2026. As the authors stress, work with your provider before changing anything.
Closed-Loop Insulin in Type 1 Diabetes Pregnancy reports a 14-center trial in Canada and Australia where closed-loop therapy raised time-in-range to 65.4% versus 50.3%, with fewer mild-to-moderate hypoglycemic events, though neonatal hyperbilirubinemia was more frequent.
Biomea Fusion completes COVALENT-211 enrollment in insulin-deficient type 2 diabetes (n=64), with Week 26 topline data anticipated in the first quarter of 2027.
That's the issue. If one thing sticks, let it be the lead: ask for the risk data in the same resolution as the benefit data, especially when insulin is already in the mix. Take care of yourselves, and check in with your care team before making changes.